Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Asset Writedowns and Impairment (2024 - 2025)

Historic Asset Writedowns and Impairment for TriSalus Life Sciences (TLSIW) over the last 2 years, with Q3 2025 value amounting to $34000.0.

  • TriSalus Life Sciences' Asset Writedowns and Impairment changed N/A to $34000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $317000.0, marking a year-over-year change of. This contributed to the annual value of $187000.0 for FY2024, which is N/A changed from last year.
  • TriSalus Life Sciences' Asset Writedowns and Impairment amounted to $34000.0 in Q3 2025.
  • TriSalus Life Sciences' 5-year Asset Writedowns and Impairment high stood at $187000.0 for Q4 2024, and its period low was $34000.0 during Q3 2025.